Document is current
Any future updates will be listed below
-
Authors
Mata, Douglas A. http://orcid.org/0000-0002-8059-8668
Benhamida, Jamal K. http://orcid.org/0000-0001-5542-9857
Lin, Andrew L.
Vanderbilt, Chad M.
Yang, Soo-Ryum
Villafania, Liliana B.
Ferguson, Donna C.
Jonsson, Philip
Miller, Alexandra M.
Tabar, Viviane
Brennan, Cameron W.
Moss, Nelson S.
Sill, Martin
Benayed, Ryma
Mellinghoff, Ingo K.
Rosenblum, Marc K.
Arcila, Maria E.
Ladanyi, Marc
Bale, Tejus A. http://orcid.org/0000-0003-3641-9287
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
- License Information
-
More Information
Article History
Received: 6 August 2020
Accepted: 13 October 2020
First Online: 9 November 2020
Compliance with ethical standards
:
: The study was approved by the MSK Institutional Review Board. Patients provided informed consent for paired tumor-normal DNA and methylation array analysis at the point of care.
: Not applicable.
: A.L. Lin reports receiving commercial research grants from NantOmics and Bristol-Myers Squibb. V. Tabar and/or her immediate family members report receiving commercial research grants from and serving as consultant/advisory board members for BlueRock Therapeutics. N. Moss has consulted for AstraZeneca. I.K. Mellinghoff reports receiving commercial research grants from Amgen, Eli Lilly, and General Electric and is a consultant/advisory board member for Agios Pharmaceuticals, Black Diamond Therapeutics, DC Europa Ltd., Debiopharm Group, Puma Biotechnology, and Voyager Therapeutics. The other authors declare that they have no competing interests.
